Article

A Reevaluation of the Clinical Significance of Histological Subtyping of Non-Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments

Division of Pathologic Anatomy, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy.
International Journal of Surgical Pathology (Impact Factor: 0.96). 08/2009; 17(3):206-18. DOI: 10.1177/1066896909336178
Source: PubMed

ABSTRACT The classification of lung cancer has always been primarily based on the morphologic assessment of routinely stained histological sections, but this approach may be difficult or even unfeasible in cytological preparations or small biopsies. Moreover, the simplistic dichotomization between small-cell carcinoma and non-small cell carcinoma (NSCLC) should be overcome, as new drugs have been discovered that are effective in specific subtypes of lung cancer. A more accurate characterization of NSCLC, however, may be hard in carcinomas lacking clear-cut signs of differentiation. The incorporation into the diagnostic algorithm of poorly differentiated carcinomas of an immunohistochemical panel including markers of squamous (high-molecular-weight cytokeratins, p63) and glandular (TTF-1, cytokeratin 7) cell differentiation seems the most promising approach. The evaluation of lung cancer for gene mutations, gene amplification, tumor-related angiogenesis, expression levels of DNA repair genes and genomic or proteomic profiles represents an exciting challenge for the pathologist in the near future.

Download full-text

Full-text

Available from: Giulio Rossi, Jun 20, 2015
2 Followers
 · 
228 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Large cell carcinoma (LCC) is a merely descriptive term indicating a subtype of lung cancer with no specific features of small-cell lung cancer (SCLC), adenocarcinoma (ADC) or squamous cell carcinoma (SQC). This diagnosis is allowed on surgical specimens only, whereas its counterpart in biopsy/cytology samples is non-small-cell lung carcinoma (NSCLC), not otherwise specified (NOS). Although these two terms do not fulfill the same concept, they can be interchangeable synonyms at the clinical level, reflecting, in different ways, the inability to define a specific subtype. Immunohistochemistry (IHC), next generation sequencing (NGS) analysis and, historically, electron microscopy have been unveiling diverse cell differentiation lineages in LCC, resulting in LCC-favor ADC, LCC-favor SQC and LCC-favor large-cell neuroendocrine carcinoma (LCNEC), the latter hopefully to be included into the neuroendocrine tumor (NET) group in the future. Paradoxically, however, the interpretation issues of LCC/NSCLC-NOS are not diminishing, but even increasing albeight an accurate diagnosis is oncologically required and crucial. Also, rare LCC/NSCLC-NOS cases exhibiting null/unclear phenotype, are difficult to classify, and this terminology could be maintained for the sake of classification (basically these tumors are serendipitous ADC, as also confirmed by the lack of p40). In this review article, seven relevant issues to LCC have been addressed by using a question-answer methodology, with final key points discussing major interpretation issues. In conclusion, most LCC/NSCLC-NOS may be eventually re-classified and addressed by exploiting IHC and/or molecular testing to satisfy the criteria of precision medicine (the right drug, to the right patient, at the right time).
    Lung Cancer 01/2015; 87(3). DOI:10.1016/j.lungcan.2015.01.008 · 3.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Esthesioneuroblastomas are rare, soft-tissue tumors that can often extend from the sinonasal cavity into the intracranial and orbital space. Prognosis depends upon the histological grade and location/extent of the tumor. Treatment often consists of maximum surgical resection followed by adjuvant chemoradiation therapy. We present a case of a patient with esthesioneuroblastoma accompanied by an extensive osteoblastic reaction leading to a significant hyperostosis along the skull base. His presenting symptoms included diplopia, and imaging revealed invasion of the orbital and intracranial spaces. Although a gross total resection of the soft tissue component of the tumor was achieved, a complete removal of the involved hyperostotic skull base could not be performed despite endoscopic endonasal and bifrontal craniotomy approaches in the same operative setting. Symptomatically, the patient improved and went on to receive chemoradiation therapy; he remained clinically and radiographically stable at 12 months. Investigation into the genetics and immunohistochemistry of this rare, hyperostotic variant of esthesioneuroblastoma may provide details regarding its aggressive nature.
    07/2013; 3. DOI:10.4303/jcrm/235673
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary Therapy for all non-small cell lung cancers has been non-selective for many decades. This was a "blind" process due to lack of solid scientific data in terms of tumor biology and molecular medicine focused in this disease. In the last decade, the study of lung cancer genome, molecular analysis, proteomics, and many others have resulted in an avalanche of knowledge which has allowed us to tailor specific treatments based on patients' tumor fingerprints ("phenotype") at the molecular level. Efforts are being conducted to see which available treatments may induce major responses that may translate into survival advantage. As an example, several predictive biomarkers in non- small cell lung cancer have been recently elucidated such as DNA repair genes (e.g., ERCC1, RRM1), gene expression profiling, certain gene mutations (e.g. EGFR, K-ras), and others. Recently, the histology of the lung tumors has become a clinical feature driving therapeutic decision. Nowadays, we consider that histology in lung cancer matters and we must secure enough tumor tissue, which can yield not only an accurate pathologic diagnosis but also for further biomarker tests. More research is needed in this arena to define the best treatment selection and therapeutic algorithm for our patients. Many variables besides patient-related factors play a crucial role in the therapeutic decision-making.